A Histologic Study of the Circadian System in Parkinson Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy

被引:51
|
作者
De Pablo-Fernandez, Eduardo [1 ,2 ]
Courtney, Robert [1 ]
Warner, Thomas T. [1 ,2 ]
Holton, Janice L. [1 ]
机构
[1] UCL, Queen Sq Brain Bank Neurol Disorders, Inst Neurol, London, England
[2] UCL, Reta Lila Weston Inst Neurol Studies, Inst Neurol, One Wakefield St, London WC1N 1PJ, England
基金
英国医学研究理事会;
关键词
RHYTHM; MELATONIN; CLOCKS; SLEEP;
D O I
10.1001/jamaneurol.2018.0640
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
IMPORTANCE Circadian dysfunction may be associated with the symptoms and neurodegeneration in Parkinson disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP), although the underlying neuroanatomical site of disruption and pathophysiological mechanisms are not fully understood. OBJECTIVE To perform a neuropathological analysis of disease-specific inclusions in the key structures of the circadian system in patients with PD, MSA, and PSP. DESIGN, SETTING, AND PARTICIPANTS This investigation was a brain bank case-control study assessing neuropathological inclusions in the suprachiasmatic nucleus (SCN) of the hypothalamus and pineal gland in healthy controls, PD (Lewy pathology), MSA (glial cytoplasmic inclusions), and PSP (tau inclusions). The study analyzed 12 healthy control, 28 PD, 11 MSA, and 21 PSP samples from consecutive brain donations (July 1, 2010, to June 30, 2016) to the Queen Square Brain Bank for Neurological Disorders and the Parkinson's UK Brain Bank, London, United Kingdom. Cases were excluded if neither SCN nor pineal tissue was available. MAIN OUTCOMES AND MEASURES Disease-specific neuropathological changes were graded using a standard semiquantitative scoring system (absent, mild, moderate, severe, or very severe) and compared between groups. RESULTS Because of limited tissue availability, the following total samples were examined in a semiquantitative histologic analysis: 5 SCNs and 7 pineal glands in the control group (6 male; median age at death, 83.8 years; interquartile range [IQR], 78.2-88.0 years), 13 SCNs and 17 pineal glands in the PD group (22 male; median age at death, 78.8 years; IQR, 75.5-83.8 years), 5 SCNs and 6 pineal glands in the MSA group (7 male; median age at death, 69.5 years; IQR, 61.6-77.7 years), and 5 SCNs and 19 pineal glands in the PSP group (13 male; median age at death, 74.3 years; IQR, 69.7-81.1 years). No neuropathological changes were found in either the SCN or pineal gland in healthy controls or MSA cases. Nine PD cases had Lewy pathology in the SCN, and only 2 PD cases had Lewy pathology in the pineal gland. All PSP cases showed inclusions in the SCN, but no PSP cases had pathology in the pineal gland. CONCLUSIONS AND RELEVANCE Disease-related neuropathological changes were found in the SCN but not in the pineal gland in PD and PSP, while both structures were preserved in MSA, reflecting different pathophysiological mechanisms that may have important therapeutic implications.
引用
收藏
页码:1008 / 1012
页数:5
相关论文
共 50 条
  • [31] Whole-Brain Atrophy Rate in Idiopathic Parkinson's Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy
    Guevara, C.
    Bulatova, K.
    Barker, G. J.
    Gonzalez, G.
    Crossley, N.
    Kempton, M. J.
    PARKINSONS DISEASE, 2016, 2016
  • [32] DYSTONIA IN PARKINSONS-DISEASE, MULTIPLE SYSTEM ATROPHY, AND PROGRESSIVE SUPRANUCLEAR PALSY
    RIVEST, J
    QUINN, N
    MARSDEN, CD
    NEUROLOGY, 1990, 40 (10) : 1571 - 1578
  • [33] MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy
    Quattrone, Aldo
    Nicoletti, Giuseppe
    Messina, Demetrio
    Fera, Francesco
    Condino, Francesca
    Pugliese, Pierfrancesco
    Lanza, Pierluigi
    Barone, Paolo
    Morgante, Letterio
    Zappia, Mario
    Aguglia, Umberto
    Gallo, Olivier
    RADIOLOGY, 2008, 246 (01) : 214 - 221
  • [34] Clinical outcomes of progressive supranuclear palsy and multiple system atrophy
    O'sullivan, S. S.
    Massey, L. A.
    Williams, D. R.
    Silveira-Moriyama, L.
    Kempster, P. A.
    Holton, J. L.
    Revesz, T.
    Lees, A. J.
    MOVEMENT DISORDERS, 2008, 23 (01) : S262 - S262
  • [35] CLINICAL OUTCOMES OF PROGRESSIVE SUPRANUCLEAR PALSY AND MULTIPLE SYSTEM ATROPHY
    O'Sullivan, S. S.
    Massey, L. A.
    Williams, D. R.
    Silveira-Moriyama, L.
    Kempster, P. A.
    Holton, J. L.
    Revesz, T.
    Lees, A. J.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2009, 80 (01): : 109 - 109
  • [36] Therapeutic Advances in Multiple System Atrophy and Progressive Supranuclear Palsy
    Poewe, Werner
    Mahlknecht, Philipp
    Krismer, Florian
    MOVEMENT DISORDERS, 2015, 30 (11) : 1528 - 1538
  • [37] Smoking habits in multiple system atrophy and progressive supranuclear palsy
    Vanacore, N
    Bonifati, V
    Fabbrini, G
    Colosimo, C
    Marconi, R
    Nicholl, D
    Bonuccelli, U
    Stocchi, F
    Lamberti, P
    Volpe, G
    De Michele, G
    Iavarone, I
    Bennett, P
    Vieregge, P
    Meco, G
    NEUROLOGY, 2000, 54 (01) : 114 - 119
  • [38] Clinical outcomes of progressive supranuclear palsy and multiple system atrophy
    O'Sullivan, S. S.
    Massey, L. A.
    Williams, D. R.
    Silveira-Moriyama, L.
    Kempster, P. A.
    Holton, J. L.
    Revesz, T.
    Lees, A. J.
    BRAIN, 2008, 131 : 1362 - 1372
  • [39] Cognitive functions in multiple system atrophy and progressive supranuclear palsy
    Skelina, S.
    Pavlova, R.
    Petrova, M.
    Mehrabian, S.
    Traykov, L. D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 101 - 101
  • [40] Diagnostic criteria for multiple system atrophy and progressive supranuclear palsy
    Wenning, G. K.
    Colosimo, C.
    REVUE NEUROLOGIQUE, 2010, 166 (10) : 829 - 833